1. Volume 12, Issue 3, Pages 263-272 (March 2011)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study 
Dr Irene M Ghobrial, MD, Edie Weller, PhD, Ravi Vij, MD, Nikhil C Munshi, MD, Ranjit Banwait, MS, Meghan Bagshaw, BA, Robert Schlossman, MD, Renee Leduc, BS, Stacey Chuma, RN, Janet Kunsman, NP, Jacob Laubach, MD, Andrzej J Jakubowiak, MD, Patricia Maiso, PhD, Aldo Roccaro, MD, Philippe Armand, MD, Akari Dollard, BA, Diane Warren, BS, Brianna Harris, BS, Tiffany Poon, BS, Amy Sam, BA, Scott Rodig, MD, Prof Kenneth C Anderson, MD, Paul G Richardson, MD 
The Lancet Oncology 
Volume 12, Issue 3, Pages (March 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1 Time-to-event analyses
Progression-free survival in all patients (A) and in phase 2 (B). Median overall survival in all patients (C) and in phase 2 (D).
The Lancet Oncology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Progression-free survival (A) and overall survival (B) in phase 2 patients refractory (n=19) or responsive (n=13) to previous treatment with bortezomib
The Lancet Oncology  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions